Clinical interpretation of prostate biopsy reports

Urology

Volumn 67, Issue 3, 2006, Pages 452-457

  Parsons, J Kellogg ^a,b   Partin, Alan W ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ANTIBODY; CYTOKERATIN 14; CYTOKERATIN 4; PROTEIN P63;

ATROPHY; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER INVASION; CANCER LOCALIZATION; CANCER STAGING; CLINICAL PRACTICE; DIAGNOSTIC TEST; DISEASE MARKER; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; NEEDLE BIOPSY; PATHOLOGIST; PERINEURIUM; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE DISEASE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW;

ADENOCARCINOMA; BIOPSY, NEEDLE; DATA INTERPRETATION, STATISTICAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE; PROSTATIC NEOPLASMS;

EID: 33644775649     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2005.11.013     Document Type: Review

References (53)

1. A.M. De Marzo, V.L. Marchi, J.I. Epstein Proliferative inflammatory atrophy of the prostate implications for prostatic carcinogenesis Am J Pathol 155 1999 1985 1992
2. A.M. De Marzo, W.G. Nelson, W.B. Isaacs Pathological and molecular aspects of prostate cancer Lancet 361 2003 955 964
3. T.Y. Chan, J.I. Epstein Follow-up of atypical prostate needle biopsies suspicious for cancer Urology 53 1999 351 355
4. K.A. Iczkowski, T.J. Bassler, V.S. Schwob Diagnosis of "suspicious for malignancy" in prostate biopsies predictive value for cancer Urology 51 1998 749 758
5. J.I. Epstein, S.R. Potter The pathological interpretation and significance of prostate needle biopsy findings implications and current controversies J Urol 166 2001 402 410
6. S. Park, K. Shinohara, G.D. Grossfeld Prostate cancer detection in men with prior high grade prostatic intraepithelial neoplasia or atypical prostate biopsy J Urol 165 2001 1409 1414
7. P.G. Borboroglu, R.L. Sur, J.L. Roberts Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate needle biopsy J Urol 166 2001 866 870
8. National Comprehensive Cancer Network: Practice Guidelines in Oncology, version 2.2005. Clinical Practice Guidelines in Oncology, 2005. Available at: www.nccn.org. Accessed September 30, 2005.
9. E.A. Allen, H. Kahane, J.I. Epstein Repeat biopsy strategies for men with atypical diagnoses on initial prostate needle biopsy Urology 52 1998 803 807
10. G.J. O'Dowd, M.C. Miller, R. Orozco Analysis of repeated biopsy results within 1 year after a noncancer diagnosis Urology 55 2000 553 559
11. G.K. Lefkowitz, G.S. Sidhu, P. Torre Is repeat prostate biopsy for high-grade prostatic intraepithelial neoplasia necessary after routine 12-core sampling? Urology 58 2001 999 1003
12. A.M. Gown, A.M. Vogel Monoclonal antibodies to intermediate filament proteins of human cells unique and cross-reacting antibodies J Cell Biol 95 1982 414 424
13. Y. Yang, J. Hao, X. Liu Differential expression of cytokeratin mRNA and protein in normal prostate, prostatic intraepithelial neoplasia, and invasive carcinoma Am J Pathol 150 1997 693 704
14. R.B. Nagle, F.R. Ahmann, K.M. McDaniel Cytokeratin characterization of human prostatic carcinoma and its derived cell lines Cancer Res 47 1987 281 286
15. S. Signoretti, D. Waltregny, J. Dilks p63 is a prostate basal cell marker and is required for prostate development Am J Pathol 157 2000 1769 1775
16. J.K. Parsons, W.R. Gage, W.G. Nelson p63 protein expression is rare in prostate adenocarcinoma implications for cancer diagnosis and carcinogenesis Urology 58 2001 619 624
17. J. Luo, S. Zha, W.R. Gage Alpha-methylacyl-CoA racemase a new molecular marker for prostate cancer Cancer Res 62 2002 2220 2226
18. M.A. Rubin, M. Zhou, S.M. Dhanasekaran Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer JAMA 287 2002 1662 1670
19. J. Xu, J.A. Stolk, X. Zhang Identification of differentially expressed genes in human prostate cancer using subtraction and microarray Cancer Res 60 2000 1677 1682
20. Z. Jiang, B.A. Woda, K.L. Rock P504S a new molecular marker for the detection of prostate carcinoma Am J Surg Pathol 25 2001 1397 1404
21. S.O. Sanderson, T.J. Sebo, L.M. Murphy An analysis of the p63/alpha-methylacyl coenzyme A racemase immunohistochemical cocktail stain in prostate needle biopsy specimens and tissue microarrays Am J Clin Pathol 121 2004 220 225
22. M. Zhou, J.I. Epstein The reporting of prostate cancer on needle biopsy prognostic and therapeutic implications and the utility of diagnostic markers Pathology 35 2003 472 479
23. J.I. Epstein Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy a diagnosis that should not be made Am J Surg Pathol 24 2000 477 478
24. H.B. Carter, P.C. Walsh, P. Landis Expectant management of nonpalpable prostate cancer with curative intent preliminary results J Urol 167 2002 1231 1234
25. J.I. Epstein, P.C. Walsh, M. Carmichael Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368 374
26. P.C. Albertsen, J.A. Hanley, D.F. Gleason Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer JAMA 280 1998 975 980
27. D.M. Steinberg, J. Sauvageot, S. Piantadosi Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings Am J Surg Pathol 21 1997 566 576
28. S.E. Spires, M.L. Cibull, D.P. Wood Jr Gleason histologic grading in prostatic carcinoma correlation of 18-gauge core biopsy with prostatectomy Arch Pathol Lab Med 118 1994 705 708
29. G.D. Grossfeld, J.J. Chang, J.M. Broering Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy results from the Cancer of the Prostate Strategic Urologic Research Endeavor database J Urol 165 2001 851 856
30. P.D. Sved, P. Gomez, M. Manoharan Limitations of biopsy Gleason grade implications for counseling patients with biopsy Gleason score 6 prostate cancer J Urol 172 2004 98 102
31. A.V. D'Amico, R. Whittington, S.B. Malkowicz Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer J Clin Oncol 18 2000 1164 1172
32. R.A. Badalament, M.C. Miller, P.A. Peller An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level J Urol 156 1996 1375 1380
33. M.L. Wills, J. Sauvageot, A.W. Partin Ability of sextant biopsies to predict radical prostatectomy stage Urology 51 1998 759 764
34. D.G. Bostwick, J. Qian, E. Bergstralh Prediction of capsular perforation and seminal vesicle invasion in prostate cancer J Urol 155 1996 1361 1367
35. O. Ukimura, P. Troncoso, E.I. Ramirez Prostate cancer staging correlation between ultrasound determined tumor contact length and pathologically confirmed extraprostatic extension J Urol 159 1998 1251 1259
36. V. Ravery, H.P. Schmid, M. Toublanc Is the percentage of cancer in biopsy cores predictive of extracapsular disease in T1-T2 prostate carcinoma? Cancer 78 1996 1079 1084
37. M.K. Terris, D.J. Haney, I.M. Johnstone Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies Urology 45 1995 75 80
38. S.J. Freedland, W.J. Aronson, G.S. Csathy Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy results from the SEARCH database Urology 61 2003 742 747
39. P.A. Peller, D.C. Young, D.P. Marmaduke Sextant prostate biopsies a histopathologic correlation with radical prostatectomy specimens Cancer 75 1995 530 538
40. T.A. Bismar, J.S. Lewis Jr, R.T. Vollmer Multiple measures of carcinoma extent versus perineural invasion in prostate needle biopsy tissue in prediction of pathologic stage in a screening population Am J Surg Pathol 27 2003 432 440
41. V.S. Tigrani, V. Bhargava, K. Shinohara Number of positive systematic sextant biopsies predicts surgical margin status at radical prostatectomy Urology 54 1999 689 693
42. H. Rogatsch, W. Horninger, H. Volgger Radical prostatectomy the value of preoperative, individually labeled apical biopsies J Urol 164 2000 754 758
43. S.S. Taneja, D.F. Penson, A. Epelbaum Does site specific labeling of sextant biopsy cores predict the site of extracapsular extension in radical prostatectomy surgical specimen J Urol 162 1999 1352 1358
44. S.P. Elliott, K. Shinohara, S.L. Logan Sextant prostate biopsies predict side and sextant site of extracapsular extension of prostate cancer J Urol 168 2002 105 109
45. S.O. Vargas, M. Jiroutek, W.R. Welch Perineural invasion in prostate needle biopsy specimens correlation with extraprostatic extension at resection Am J Clin Pathol 111 1999 223 228
46. A.J. Egan, D.G. Bostwick Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings perineural invasion lacks significance on multivariate analysis Am J Surg Pathol 21 1997 1496 1500
47. A. de la Taille, A. Katz, E. Bagiella Perineural invasion on prostate needle biopsy an independent predictor of final pathologic stage Urology 54 1999 1039 1043
48. A. de la Taille, M.A. Rubin, E. Bagiella Can perineural invasion on prostate needle biopsy predict prostate specific antigen recurrence after radical prostatectomy? J Urol 162 1999 103 106
49. J.I. Epstein The role of perineural invasion and other biopsy characteristics as prognostic markers for localized prostate cancer Semin Urol Oncol 16 1998 124 128
50. G.F. Holmes, P.C. Walsh, C.R. Pound Excision of the neurovascular bundle at radical prostatectomy in cases with perineural invasion on needle biopsy Urology 53 1999 752 756
51. M.A. Rubin, T.A. Bismar, S. Curtis Prostate needle biopsy reporting how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients? Am J Surg Pathol 28 2004 946 952
52. H.B. Carter, J. Sauvageot, P.C. Walsh Prospective evaluation of men with stage T1c adenocarcinoma of the prostate J Urol 157 1997 2206 2209
53. M.A. Khan, H.B. Carter, J.I. Epstein Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 170 2003 2274 2278